Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A dose-block randomized, double-blind, placebo-controlled, single dosing, dose-escalation phase I clinical trial to investigate the safety/tolerability and pharmacokinetics of HNP-2006 after intravenous administration in healthy adult volunteers

Trial Profile

A dose-block randomized, double-blind, placebo-controlled, single dosing, dose-escalation phase I clinical trial to investigate the safety/tolerability and pharmacokinetics of HNP-2006 after intravenous administration in healthy adult volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 02 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HNP 2006 (Primary)
  • Indications CNS cancer
  • Focus Pharmacokinetics
  • Sponsors Hana Pharm

Most Recent Events

  • 24 Mar 2023 Results assessing safety, tolerability, and pharmacokinetics (PKs) of HNP-2006 after a single intravenous (IV) administration in healthy subjects, presented at the 124th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
  • 01 Dec 2020 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top